Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904).
Koichi Takayama
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Taiho Pharmaceutical
Koji Inoue
No relevant relationships to disclose
Masafumi Takeshita
No relevant relationships to disclose
Naoki Tashiro
No relevant relationships to disclose
Taishi Harada
No relevant relationships to disclose
Takashi Seto
Honoraria - Bristol-Myers Squibb; Lilly; Nippon Kayaku
Tomotoshi Imanaga
No relevant relationships to disclose
Noriko Fujimoto
No relevant relationships to disclose
Noriaki Nakagaki
No relevant relationships to disclose
Masayuki Kawasaki
No relevant relationships to disclose
Junji Kishimoto
No relevant relationships to disclose
Yukito Ichinose
Honoraria - Bristol-Myers Squibb; Lilly; Nippon Kayaku